Optas, LLC Eli Lilly & CO Transaction History

Optas, LLC

$429 Million
Q3 2024

A detailed history of Optas, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Optas, LLC holds 4,269 shares of LLY stock, worth $3.4 Million. This represents 0.88% of its overall portfolio holdings.

Number of Shares

4,269

Previous 2,601 64.13%

Holding current value

$3.4 Million

Previous $2.35 Million 60.66%

% of portfolio

0.88%

Previous 0.61%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 29, 2024	BUY	$772.14 - $960.02 $1.29 Million - $1.6 Million	1,668 Added 64.13%	4,269 $3.78 Million
Q2 2024 Jul 25, 2024	BUY	$724.87 - $909.04 $72,487 - $90,904	100 Added 4.0%	2,601 $2.35 Million
Q1 2024 Apr 17, 2024	BUY	$592.2 - $792.28 $31,386 - $41,990	53 Added 2.17%	2,501 $1.95 Million
Q4 2023 Jan 25, 2024	BUY	$525.19 - $619.13 $196,421 - $231,554	374 Added 18.03%	2,448 $1.43 Million
Q3 2023 Oct 31, 2023	BUY	$434.7 - $599.3 $358,627 - $494,422	825 Added 66.05%	2,074 $1.11 Million
Q2 2023 Jul 20, 2023	BUY	$350.74 - $468.98 $23,148 - $30,952	66 Added 5.58%	1,249 $585,000
Q1 2023 Apr 17, 2023	BUY	$310.63 - $364.82 $27,646 - $32,468	89 Added 8.14%	1,183 $406,000
Q4 2022 Jan 27, 2023	BUY	$321.55 - $374.67 $16,720 - $19,482	52 Added 4.99%	1,094 $400,000
Q3 2022 Oct 31, 2022	BUY	$296.48 - $337.87 $6,522 - $7,433	22 Added 2.16%	1,042 $337,000
Q2 2022 Aug 01, 2022	BUY	$278.73 - $327.27 $52,401 - $61,526	188 Added 22.6%	1,020 $330,000
Q1 2022 Apr 26, 2022	BUY	$234.69 - $291.66 $195,262 - $242,661	832 New	832 $238,000
Q4 2020 Jan 27, 2021	SELL	$130.46 - $172.63 $200,125 - $264,814	-1,534 Closed	0 $0
Q3 2020 Oct 23, 2020	BUY	$146.22 - $169.13 $224,301 - $259,445	1,534 New	1,534 $226,000

Others Institutions Holding LLY

# of Institutions

4,011

Shares Held

751M

Call Options Held

8.27M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Optas, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Optas, LLC with notifications on news.

Account